Intranasal Vaccine Breakthrough: Unlocking Stronger Immunity Against Sarbecoviruses
A collaborative study between NUS Medicine and Monash University has unveiled a groundbreaking vaccine booster that could revolutionize our fight against respiratory viruses.
The research team, led by Associate Professor Sylvie Alonso and Dr. Nicholas Cheang, has developed a novel intranasal booster vaccine, Clec9AOMNI, which targets dendritic cells and harnesses the power of a DC-targeting platform. But here's where it gets intriguing: this vaccine booster is administered through the nose, offering a unique approach to bolstering immunity.
Unlocking the Power of Nasal Vaccination
The study, published in The Journal of Clinical Investigation, compared the intranasal Clec9AOMNI booster with conventional intramuscular mRNA boosters. And the results were remarkable! Clec9AOMNI triggered significantly stronger neutralizing antibody responses and robust T-cell responses in the lungs and nasal tissues, providing a one-two punch against sarbecoviruses, a group of coronaviruses that includes SARS-CoV-2 and SARS-CoV-1.
Overcoming Current Vaccine Challenges
The researchers addressed a critical issue with existing COVID-19 mRNA vaccines: their limited ability to induce mucosal immunity and protect against a broad range of sarbecoviruses. Clec9AOMNI, however, demonstrated its potential to provide long-lasting and broad immunity against SARS-CoV-2 variants, suggesting a possible end to the cycle of repeated booster shots.
'Our intranasal vaccine candidate, Clec9AOMNI, may offer a more comprehensive solution by generating robust immunity at mucosal surfaces, which are often the first line of defense against respiratory viruses,' said Assoc Prof Alonso. This is particularly crucial for vulnerable populations who may not respond well to traditional intramuscular vaccines.
A New Avenue for Vaccine Design
The Clec9A platform, which targets dendritic cells, is a key innovation. Dendritic cells play a pivotal role in initiating adaptive immune responses, and by leveraging this mechanism, the intranasal booster vaccine shows promise in preventing infections at the entry point of viruses. This approach could be a game-changer in the ongoing battle against respiratory viruses and future pandemics.
'This study opens up exciting possibilities for vaccine development, especially for respiratory diseases,' noted Assoc Prof Mireille Lahoud. The team's next steps include validating their findings in human-relevant models, with the ultimate goal of applying this versatile and cost-effective strategy to a wide range of infectious and non-infectious diseases.
This research is part of a larger effort funded by the Singapore Ministry of Health and MOH Holdings Pte Ltd, highlighting the importance of such innovations in epidemic preparedness and response.
For more information, contact the research team at the provided media contacts.
*What are your thoughts on this innovative approach to vaccine development? Could intranasal boosters be the future of respiratory virus protection? Share your insights below!
